766557-02-2

Usage

Uses

Used in Organic Synthesis:
6-Chloroindole-3-carboxylic acid is used as a chemical reagent for its role in organic synthesis processes. It serves as a building block for the creation of more complex molecules, which can be further utilized in various applications.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 6-Chloroindole-3-carboxylic acid is used as a key intermediate in the synthesis of various drugs. Its unique structure allows for the development of new compounds with potential therapeutic properties, contributing to the advancement of medicine.
Used in Research and Development:
6-Chloroindole-3-carboxylic acid is also employed in research and development settings, where it is used to study the effects of chlorination on indole-based compounds. This can lead to a better understanding of the properties and potential applications of these compounds in various fields.

InChI:InChI=1/C9H6ClNO2/c10-5-1-2-6-7(9(12)13)4-11-8(6)3-5/h1-4,11H,(H,12,13)

Upstream product

• 1144460-70-7 6-chloro-1H-indole-3-carbaldehyde oxime 
• 194490-17-0 6-chloro-1H-indole-3-carbonitrile 
• 703-82-2 6-chloro-1H-indole-3-carbaldehyde 
• 676477-10-4 1-(6-chloro-1H-indol-3-yl)-2,2,2-trifluoroethan-1-one 
• 17422-33-2 6-chloroindole 

Downstream Products

• 17422-33-2 6-chloroindole 
• 920022-47-5 [6-chloro-1-[2-(dimethylamino)ethyl]indol-3-yl]-spiro[1H-isobenzofuran-3,4′-piperidine]-1′-yl-methanone 
• 921194-97-0 methyl 6-chloro-1H-indole-3-carboxylate 

Relevant academic research and scientific papers

Novel indole derivative and medicine containing the same (by machine translation)

[A] formation of Amyloid fibrils can be compounds, including therapeutic or prophylactic agent for neurodegenerative disease Amyloid fibrils formation inhibitor compound and of. (I) or its pharmaceutically acceptable compound represented by the formula [a] or a salt or solvate thereof includes the, Amyloid fibrils formation inhibitor. [R1 And R2 Each independently is H, an alkyl group, a cyano group or the like; R3 And R4 Each independently is H, or an alkyl group; R3 And R4 The, joint may form a ring; Ar1 And Ar2 The substituted or unsubstituted heteroaryl group are independently substituted/unsubstituted aryl groups /; X and Y are each independently a single bond, - (=O) - C etc., Z is O or CH2 ; N is an integer of 1 - 3][Drawing] no (by machine translation)

Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach

From a micromolar high throughput screening hit 7, the successful complementary application of a chemogenomic approach and of a scaffold hopping exercise rapidly led to a low single digit nanomolar human vasopressin 1a (hV1a) receptor antagonist 38. Initial optimization of the mouse V1a activities delivered suitable tool compounds which demonstrated a V1a mediated central in vivo effect. This novel series was further optimized through parallel synthesis with a focus on balancing lipophilicity to achieve robust aqueous solubility while avoiding P-gp mediated efflux. These efforts led to the discovery of the highly potent and selective brain-penetrant hV1a antagonist RO5028442 (8) suitable for human clinical studies in people with autism.

NOVEL BIS-INDOLIC DERIVATIVES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG

The present invention relates to novel bis-indolic derivatives, processes for their preparation, and their potential use as new antibacterial drugs.

BIS-INDOLIC DERIVATIVES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG

The present invention relates to novel bis-indolic derivatives, processes for their preparation, and their potential use as new antibacterial drugs.

An investigation into the substituent effect of halogen atoms on the crystal structures of indole-3-carboxylic acid (ICA)

An investigation into the substituent effect of halogen atoms (F, Cl, Br) on the crystal structure of indole-3-carboxylic acid (ICA) was prepared in this work. The investigation was done through the aspect of crystal structure, intermolecular interactions and π...π stacking motifs with the assistance of infrared spectra, elemental analyses, NMR spectra, differential scanning calorimetry (DSC), thermogravimetric analyses (TGA) and hot stage microscopy (HSM) measurements. The results revealed that the different kinds of halogen atoms and the different substituted positions have a significant effect on the crystal structures, molecular π...π stacking motifs and the kinds of intermolecular interactions. We further correlated the melting points of the ICAs with the H-H, O-H and X-H (X = F, Cl, Br) interactions, and found a positive correlation between them.

AZASPIRO DERIVATIVES

The present invention is concerned with novel indol-3-yl-carbonyl-azaspiropiperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorder

Indol-3-yl-carbonyl-azaspiro derivatives

This invention relates to indol-3-yl-carbonyl-azaspiro derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the azaspiro-head group A and the residues R1, R2 and R3 are as defin

Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives

The present invention relates to Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R1 to R7 are as defined herein. The invention

Indol-3-yl-carbonyl-spiro-piperidine derivatives

This invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as Via receptor antagonists and which are represented by Formula I: wherein the spiropiperidine-head group A and the residues R1, R2 and R3 /s